Ono Pharmaceutical Co., Ltd.
OPHLY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $486,871 | $502,672 | $447,187 | $361,361 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Cost of Goods Sold | $147,950 | $127,126 | $110,062 | $93,511 |
| Gross Profit | $338,921 | $375,546 | $337,125 | $267,850 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| R&D Expenses | $149,866 | $112,377 | $95,344 | $75,879 |
| G&A Expenses | $91,568 | $73,370 | $68,806 | $62,623 |
| SG&A Expenses | $122,219 | $97,389 | $86,643 | $74,119 |
| Sales & Mktg Exp. | $30,651 | $24,019 | $17,837 | $11,496 |
| Other Operating Expenses | $7,089 | $2,677 | $13,174 | $14,656 |
| Operating Expenses | $279,174 | $212,443 | $195,161 | $164,654 |
| Operating Income | $59,747 | $163,103 | $141,963 | $103,195 |
| % Margin | 12.3% | 32.4% | 31.7% | 28.6% |
| Other Income/Exp. Net | -$419 | $631 | $1,569 | $1,830 |
| Pre-Tax Income | $59,328 | $163,734 | $143,532 | $105,025 |
| Tax Expense | $9,163 | $35,694 | $30,619 | $24,340 |
| Net Income | $50,047 | $127,977 | $112,723 | $80,519 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS | 35.52 | 88.86 | 76.94 | 54.06 |
| % Growth | -60% | 15.5% | 42.3% | – |
| EPS Diluted | 35.47 | 88.87 | 76.92 | 54.05 |
| Weighted Avg Shares Out | 1,411 | 1,440 | 4,395 | 4,469 |
| Weighted Avg Shares Out Dil | 1,409 | 1,440 | 4,396 | 4,469 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,774 | $4,027 | $2,478 | $2,710 |
| Interest Expense | $5,318 | $229 | $913 | $874 |
| Depreciation & Amortization | $26,894 | $18,140 | $17,451 | $17,721 |
| EBITDA | $91,540 | $178,435 | $161,896 | $123,620 |
| % Margin | 18.8% | 35.5% | 36.2% | 34.2% |